A randomised placebo-controlled double-blind study in patients with Huntington’s disease demonstrated a dose-dependent decrease in the concentration of mutant HTT in the cerebrospinal fluid (CSF) following intrathecal administration of HTTRx [55]. Here, HTT is linked to juvenile Huntington disease.